QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:LTRN

Lantern Pharma Stock Forecast, Price & News

$6.60
-0.67 (-9.22%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.47
$7.45
50-Day Range
$6.60
$9.96
52-Week Range
$6.47
$23.50
Volume
133,883 shs
Average Volume
89,062 shs
Market Capitalization
$73.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.54
30 days | 90 days | 365 days | Advanced Chart
Receive LTRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.


Lantern Pharma logo

About Lantern Pharma

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Headlines

Lantern Pharma Announces Share Repurchase Program
November 22, 2021 |  finance.yahoo.com
LTRN: 3Q:21 Results
November 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LTRN
Fax
N/A
Employees
13
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.88 per share

Profitability

Net Income
$-5.91 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
7,798,000
Market Cap
$73.84 million
Optionable
Not Optionable

Company Calendar

Last Earnings
10/31/2021
Today
1/18/2022
Next Earnings (Estimated)
3/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

574th out of 1,414 stocks

Pharmaceutical Preparations Industry

276th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Lantern Pharma (NASDAQ:LTRN) Frequently Asked Questions

Is Lantern Pharma a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lantern Pharma stock.
View analyst ratings for Lantern Pharma
or view top-rated stocks.

Are investors shorting Lantern Pharma?

Lantern Pharma saw a decline in short interest in December. As of December 15th, there was short interest totaling 189,300 shares, a decline of 17.7% from the November 30th total of 230,100 shares. Based on an average daily trading volume, of 82,700 shares, the days-to-cover ratio is presently 2.3 days. Approximately 2.4% of the shares of the stock are short sold.
View Lantern Pharma's Short Interest
.

When is Lantern Pharma's next earnings date?

Lantern Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Lantern Pharma
.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) released its quarterly earnings data on Sunday, October, 31st. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.09. During the same quarter last year, the business posted ($0.27) earnings per share.
View Lantern Pharma's earnings history
.

What price target have analysts set for LTRN?

2 Wall Street analysts have issued 12 month price targets for Lantern Pharma's shares. Their forecasts range from $29.00 to $34.00. On average, they anticipate Lantern Pharma's share price to reach $31.50 in the next twelve months. This suggests a possible upside of 377.3% from the stock's current price.
View analysts' price targets for Lantern Pharma
or view top-rated stocks among Wall Street analysts.

Who are Lantern Pharma's key executives?

Lantern Pharma's management team includes the following people:
  • Mr. Panna Sharma, Pres, CEO & Director (Age 50, Pay $750.49k)
  • Mr. David R. Margrave, CFO & Sec. (Age 60, Pay $298.88k)
  • Dr. Kishor Gopaldas Bhatia Ph.D., Chief Scientific Officer & Scientific Consultant (Age 66, Pay $92.89k)
  • Dr. Peter L. Nara D.V.M., M.S., Ph.D., Co-Founder & Advisor

What other stocks do shareholders of Lantern Pharma own?

When did Lantern Pharma IPO?

(LTRN) raised $26 million in an IPO on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

What is Lantern Pharma's stock symbol?

Lantern Pharma trades on the NASDAQ under the ticker symbol "LTRN."

Who are Lantern Pharma's major shareholders?

Lantern Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Spire Wealth Management (0.04%).

Which institutional investors are buying Lantern Pharma stock?

LTRN stock was purchased by a variety of institutional investors in the last quarter, including Spire Wealth Management.

How do I buy shares of Lantern Pharma?

Shares of LTRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantern Pharma's stock price today?

One share of LTRN stock can currently be purchased for approximately $6.60.

How much money does Lantern Pharma make?

Lantern Pharma has a market capitalization of $73.84 million. The company earns $-5.91 million in net income (profit) each year or ($1.28) on an earnings per share basis.

How many employees does Lantern Pharma have?

Lantern Pharma employs 13 workers across the globe.

What is Lantern Pharma's official website?

The official website for Lantern Pharma is www.lanternpharma.com.

Where are Lantern Pharma's headquarters?

Lantern Pharma is headquartered at 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201.

How can I contact Lantern Pharma?

Lantern Pharma's mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The company can be reached via phone at 972-277-1136 or via email at [email protected].


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.